Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Age of patient when antidepressant(s) prescribed:

What condition was this medication prescribed to treat?

What additional medications were you taking at the time?

Did patient hurt themselves during or after taking the drug?

Did patient become violent during or after taking the drug?

Was suicide attempted?

Was hospitalization or institutionalization required after taking antidepressant(s)?

Did loved one commit suicide?

If patient did attempt or commit suicide, did patient ever attempt suicide previously?

If patient did commit suicide, what was the method of suicide?

Please describe violent or suicidal behavior:

If you ever tried to stop taking Paxil and experienced withdrawal, please describe the withdrawal side effects:

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Paxil Increases Suicide Risk: Report

Aug 22, 2005 | CNN/Money

Paxil, a blockbuster antidepressant from British drug maker GlaxoSmithKline, increases the risk of suicide in adults, according to a study by Norwegian researchers.

Patients taking Paxil, a $1.9 billion drug also known by its generic term paroxetine, attempted suicide seven times, compared to one suicide attempt in placebo studies, according to a report by Ivar Aursnes and other Norwegian researchers and published in BMC Medicine on Aug. 22.

"Summarizing the suicide attempts, there are seven among the patients on paroxetine and one among the patients on placebo," read the report, which said there were 16 studies conducted with 916 patients on Paxil and 550 on placebo.

GlaxoSmithKline (down $0.06 to $48.15, Research), a London-based drug maker with $39 billion in 2004 sales, criticized the study as "misleading" and based on outdated and "incorrectly selected" data.

"The company disagrees with the conclusion from the sub-analysis conducted by scientists based in Oslo," said GlaxoSmithKline in a prepared statement. "It serves only to cause confusion and unnecessary concern for patients using an SSRI (selective serotonin reuptake inhibitor,) such as paroxetine, for treatment of depression."

The suicidal side effects of antidepressants has raised concerns with the Food and Drug Administration, which now requires all antidepressants to carry warnings about the increased risk of suicide to children and teenagers. On June 30, the FDA said it is conducting a review of available data to determine whether there is an increased risk of suicidal thinking in adults who are taking antidepressants. The FDA expects to take at least a year to complete this review.

The scientists who conducted the Paxil study suggested that adults be included in regulatory warnings.

"We also conclude that the recommendation of restrictions on the use of paroxetine for children and adolescents recently conveyed by regulatory agencies should be extended to include usage by adults," read the report.

Related articles Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo